Clinical trials: Acute Rejection of Liver Transplant
Acute Rejection of Liver Transplant, Effects of Immunosuppressant Therapy
SRL (Sirolimus) Withdrawal
The significance of this clinical trial lies in its potential to increase the success of immunosuppression (IS) therapy withdrawal in liver transplant (LT) recipients, thus decreasing the negative impact of IS on their long-term…
- Trial name
- SRL (NCT02062944)
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Northwestern University
Intestinal Microbiota, Complication of Transplanted Liver
Human Microbiota and Liver Transplant
The microbiota represents the collections of microbial communities that colonize a host. In health, the microbiota protects against pathogens and maturation of the immune system.
- Conditions
- Intestinal Microbiota, Complication of Transplanted Liver, Acute Rejection of Liver Transplant, Infection
- Trial name
- NCT02223468
- Where
- Spain
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hospital Vall d'Hebron
Liver Failure, Liver Failure, Acute
Use of N-Acetylcysteine During Liver Procurement
Randomized prospective study on the impact on the post-LT outcome by the infusion of N-acetylcysteine (NAC) during the liver procurement procedure, as an anti-oxidant agent to reduce the ischemia-reperfusion damage of organs for…
- Conditions
- Liver Failure, Liver Failure, Acute, Liver Diseases, Carcinoma, Hepatocellular
- Trial name
- NCT01394497
- Testing
- N-acetylcystein
- Where
- Italy
- Volunteers
- 140 people
- Sponsor
- Azienda Ospedaliera di Padova
Acute Cellular Graft Rejection, New Onset Diabetes After Transplant
Budesonide for Liver Transplant Immune Suppression
This is a pilot study that investigates the efficacy and safety of budesonide as an immune suppressing agent for liver transplant recipients in the early post-transplant period.
- Trial name
- NCT03304626
- Testing
- Budesonide 3Mg Capsule, Standard of Care Prednisone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Cincinnati
Liver Transplant Rejection
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.
Our study aimed at studying the impact of gene polymorphism of NFKBIA and PTPN22 genes on rejection episodes in liver transplant Egyptian recipients. Also assess patients' factors associated with graft rejection.
- Trial name
- NCT06060808
- Testing
- gene polymorphism
- Where
- Egypt
- Volunteers
- 105 people
- Sponsor
- Helwan University
Hepatocellular Carcinoma, Acute Rejection
Effect of PD-1 /PD-L1 Inhibitor Therapy Before Liver Transplantation on Acute Rejection After Liver Transplantation in Patients With Hepatocellular Carcinoma
This study is a single-center, prospective, non-interventional cohort study based on the real world data.In this study, 30 patients with a history of PD-1/PD-L1 monotherapy prior to liver transplantation and 30 patients without a…
- Trial name
- NCT05411926
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Acute Liver Failure, Acute-On-Chronic Liver Failure
Role of Fecal Microbiota in Predicting Graft Rejection and Sepsis Among Recipients of Living Donor Liver Transplant in First Year.
Efficient immunosuppressive therapy and improved surgical techniques have developed liver transplantation as a well-established and life-saving treatment. The 1-year survival rate of approximately 85-90%.
- Conditions
- Acute Liver Failure, Acute-On-Chronic Liver Failure, Liver Cirrhosis
- Trial name
- NCT04621812
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Liver Transplantation
A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Liver Transplant Patients.
This 2 arm study will compare the efficacy and safety of two CellCept-containing treatment regimens in de novo liver transplant patients.
- Trial name
- NCT00545402
- Testing
- Mycophenolate mofetil, adjusted dose, Tacrolimus, Corticosteroids, IV
- Where
- 16 sites in France
- Volunteers
- 180 people
- Sponsor
- Hoffmann-La Roche
Renal Insufficiency
Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction
Renal dysfunction in the context of liver transplantation is a major issue, with difficult patients' management and determining a worsened prognosis.
- Trial name
- ATG_HVH (NCT01453218)
- Testing
- ATeGe-Fresenius
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Hospital Vall d'Hebron
Complication of Transplanted Liver
Donor Specific HLA Alloantibodies in Liver Transplantation
The aim is to evaluate the impact of donor specific HLA alloantibodies (DSA) on all-cause mortality and re-transplantation, early allograft dysfunction, acute and chronic rejection, fibrosis, vascular, and biliary complications.
- Trial name
- NCT02784080
- Testing
- HLA-alloantibodies exposure
- Where
- 5 sites in Denmark, Finland and 2 more
- Volunteers
- 858 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Renal Function, Liver Transplant
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
This study was designed to assess the evolution of renal function and to collect efficacy, safety, and tolerability data of everolimus in co-exposure with reduced CNI in paediatric liver transplant recipients.
- Trial name
- NCT01598987
- Testing
- Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.
- Where
- 32 sites in United States, Australia and 10 more
- Volunteers
- 56 people
- Sponsor
- Novartis Pharmaceuticals
Graft Rejection, Heart Transplantation
Diagnostic Validity of [18F]FSPG PET for the Assessment of Acute Rejection After Heart or Liver Transplantation
The a series of clinical studies of [18F]FSPG PET/CT showed that [18F]FSPG is safe and promising PET tracer for detecting inflammation with favorable biodistribution and pharmacokinetics in patients.
- Conditions
- Graft Rejection, Heart Transplantation, Liver Transplantation
- Trial name
- NCT04488094
- Testing
- [18F]FSPG
- Where
- South Korea
- Volunteers
- 7 people
- Sponsor
- Asan Medical Center
Rejection Acute Hepatic, Transplant; Failure, Liver
Single-center Prospective Study of Non-invasive Methods for the Diagnosis of Postoperative Complications in Liver Transplant Recipients
A lot of different early and late complications may occur after liver transplantation. They could be related to surgical procedure, to infectious diseases or immuno-mediated diseases (acute cellular rejection, ACR).
- Conditions
- Rejection Acute Hepatic, Transplant; Failure, Liver, Liver Dysfunction
- Trial name
- ElastOLT (NCT05793203)
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Evidence of Liver Transplantation
Reduction of Tacrolimus Dose in Association With Mycophenolate Mofetil After Liver Transplantation
The prevention of graft rejection after liver transplantation benefits nowadays from a variety of newly developed immunosuppressive agents.
- Trial name
- MMF-FK (NCT00151632)
- Testing
- Mycophenolate mofetil, Tacrolimus
- Where
- 8 sites in France
- Volunteers
- 195 people
- Sponsor
- Rennes University Hospital
Acute Graft Rejection
Diagnosis of Graft Pathology by TruGraf
The goal of this observational study is to to identify different causes of liver diseases or damage in liver transplant patients and develop a machine learning algorithm as a non-invasive tool leveraging gene expression and…
- Trial name
- NCT06557564
- Testing
- TruGraf liver gene expression
- Where
- Canada
- Volunteers
- 471 people
- Sponsor
- University Health Network, Toronto
Liver Transplant, Hepatitis C
Proteogenomic Monitoring and Assessment of Liver Transplant Recipients
This study is being done to test blood, urine and tissue samples to see if this can help decide if CKD (Chronic Kidney Disease), AR (Acute Rejection) and HCV (Hepatitis C Virus) can be identified in its early stages.
- Conditions
- Liver Transplant, Hepatitis C, Chronic Kidney Disease, Acute Rejection
- Trial name
- "Mini-Liver" (NCT01644903)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Northwestern University
Immunosuppression After Liver Transplantation
Conversion Prograf® to Advagraf® at D7 Versus D90 After Liver Transplantation
The best period for the conversion from Prograf (tacrolimus administered twice daily) to Advagraf (once-daily prolonged-release tacrolimus) remains unknown.
- Trial name
- Conversion (NCT02105155)
- Testing
- Conversion at day 7 ± 3 Prograf® to Advagraf®, Conversion at day 90±5 Prograf® to Advagraf®
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Rejection; Transplant, Liver
Transcriptomics as an Aid in the Histological Diagnosis of Acute Rejection After Liver Transplantation
The primary objective of this exploratory study is to identify genes associated with acute rejection in liver transplant patients.
- Trial name
- NCT06734013
- Testing
- Molecular diagnostic
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Liver Transplantation
Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant
This two-arm study will assess the efficacy and safety of a long-term calcineurin inhibitor-free maintenance regimen with CellCept and sirolimus in recipients of an orthotropic liver transplant.
- Trial name
- NCT00118742
- Testing
- mycophenolate mofetil [CellCept], Tacrolimus, Cyclosporine
- Where
- 46 sites in United States, Canada
- Volunteers
- 293 people
- Sponsor
- Hoffmann-La Roche